CareDx, Inc. — Form 8-K/A
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 78/100
What the filing says
On April 28, 2026, CareDx agreed to acquire precision oncology diagnostics company Naveris, Inc. for $160.0 million in upfront cash consideration plus up to $100.0 million in contingent consideration based on specified revenue milestones for years ending December 31, 2026 and 2027. The transaction closed July 1, 2026. Naveris generated $34.3 million in revenue for 2025 (primarily from its NavDx HPV blood test) and had an accumulated deficit of $65.0 million; CareDx valued acquired intangible assets at $125.1 million and recorded $71.8 million in goodwill.
Why this rating
Acquisition adds complementary precision oncology testing platform; material relative to CareDx size (~$1B market cap); revenue synergies significant but integration risk and contingent payment structure warrant cautious optimism.
Price action (we called it positive)
before filing · preread $53.55 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.